New Day Diagnostics

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, New Day Diagnostics sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials none currently recruiting 1 completed upper half by trial count

New Day Diagnostics: 2 sponsored US clinical trials, none currently recruiting.

New Day Diagnostics sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. The most-studied condition in this pipeline is Polyps, with 1 trials.

Mid-pack sponsor footprint

New Day Diagnostics is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Indexed trials (enrollment closed)

2 total, page 1 of 1

ACTIVE NOT RECRUITING

CRC Detection Reliable Assessment With Blood

NCT05551052
COMPLETED NA

COVID-19 iCura SARS-CoV-2 Ag OTC: Clinical Evaluation

NCT05555030

Therapeutic Areas

Polyps 1
Colon Polyp 1
Colon Disease 1
Colon Lesion 1
Colon Neoplasm 1
Adenomas Colon 1
Adenoma 1
Colon Cancer 1
Rectal Cancer 1
Colorectal Cancer 1

How the New Day Diagnostics archive is shaped

2 indexed studies, none listed as recruiting (0% open); 1 completed (50%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Polyps (1 trial), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

New Day Diagnostics: archived-pipeline peers nationwide

Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

New Day Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share New Day Diagnostics1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
New Day Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

New Day Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this New Day Diagnostics page

2 registered trials is a research-attention snapshot, not an endorsement of New Day Diagnostics or any single study.

  • None of New Day Diagnostics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Polyps is the condition New Day Diagnostics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Polyps trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

New Day Diagnostics pipeline card: 2 registered trials from official public datasets.Report a data error.